Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
CDNA Price Action
Last 7 days
5.9%
Last 30 days
27.7%
Last 90 days
44.0%
Trailing 12 Months
-24.4%
CDNA RSI Chart
CDNA Valuation
CDNA Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
CDNA Fundamentals
CDNA Revenue
CDNA Earnings
CDNA Profitability
CDNA Investor Care
CDNA Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 346.4M | 340.8M | 358.0M | 0 |
| 2024 | 275.1M | 297.1M | 312.8M | 333.8M |
| 2023 | 319.6M | 309.3M | 297.1M | 280.3M |
| 2022 | 308.4M | 314.9M | 318.6M | 321.8M |
| 2021 | 221.2M | 253.6M | 275.8M | 296.4M |
| 2020 | 139.5M | 149.8M | 169.4M | 192.2M |
| 2019 | 88.5M | 102.1M | 114.8M | 127.1M |
| 2018 | 50.8M | 56.6M | 65.6M | 76.6M |
| 2017 | 45.7M | 47.0M | 46.7M | 48.3M |
| 2016 | 27.5M | 31.1M | 36.4M | 40.6M |
| 2015 | 28.6M | 29.0M | 29.4M | 28.1M |
| 2014 | 23.0M | 24.4M | 25.2M | 27.3M |
| 2013 | 20.9M | 21.3M | 21.7M | 22.1M |
| 2012 | 0 | 0 | 0 | 20.5M |
Get all data in R, Python etc through our Historical Stock Data APIs
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| CEO | Dr. Reginald Seeto M.D., MBBS |
|---|---|
| WEBSITE | caredx.com |
| SECTOR | Healthcare |
| INDUSTRY | Diagnostics & Research |
| EMPLOYEES | 727 |
